Lördag 21 December | 15:28:22 Europe / Stockholm

Kalender

Tid*
2026-02-03 N/A Bokslutskommuniké 2025
2025-10-21 N/A Kvartalsrapport 2025-Q3
2025-07-22 N/A Kvartalsrapport 2025-Q2
2025-04-29 N/A Kvartalsrapport 2025-Q1
2025-03-12 N/A Årsstämma
2025-02-05 N/A Bokslutskommuniké 2024
2024-10-22 - Kvartalsrapport 2024-Q3
2024-07-23 - Kvartalsrapport 2024-Q2
2024-04-23 - Kvartalsrapport 2024-Q1
2024-03-13 - Årsstämma
2024-03-13 - X-dag ordinarie utdelning EMBLA 0.00 DKK
2024-03-12 - Årsstämma
2024-01-30 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-07-25 - Kvartalsrapport 2023-Q2
2023-04-25 - Kvartalsrapport 2023-Q1
2023-03-13 - X-dag ordinarie utdelning EMBLA 0.00 DKK
2023-03-10 - Årsstämma
2023-01-31 - Bokslutskommuniké 2022
2022-10-25 - Kvartalsrapport 2022-Q3
2022-07-21 - Kvartalsrapport 2022-Q2
2022-04-26 - Kvartalsrapport 2022-Q1
2022-03-09 - X-dag ordinarie utdelning EMBLA 0.00 DKK
2022-03-08 - Årsstämma
2022-02-01 - Bokslutskommuniké 2021
2021-10-26 - Kvartalsrapport 2021-Q3
2021-07-22 - Kvartalsrapport 2021-Q2
2021-04-27 - Kvartalsrapport 2021-Q1
2021-03-09 - X-dag ordinarie utdelning EMBLA 0.00 DKK
2021-03-08 - Årsstämma
2021-02-02 - Bokslutskommuniké 2020
2020-10-27 - Kvartalsrapport 2020-Q3
2020-07-23 - Kvartalsrapport 2020-Q2
2020-04-30 - Kvartalsrapport 2020-Q1
2020-03-13 - X-dag ordinarie utdelning EMBLA 0.15 DKK
2020-03-12 - Årsstämma
2020-02-04 - Bokslutskommuniké 2019
2019-10-22 - Kvartalsrapport 2019-Q3
2019-07-25 - Kvartalsrapport 2019-Q2
2019-04-30 - Kvartalsrapport 2019-Q1
2019-03-08 - X-dag ordinarie utdelning EMBLA 0.14 DKK
2019-03-07 - Årsstämma
2019-02-05 - Bokslutskommuniké 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-07-25 - Kvartalsrapport 2018-Q2
2018-04-25 - Kvartalsrapport 2018-Q1
2018-03-09 - X-dag ordinarie utdelning EMBLA 0.13 DKK
2018-03-08 - Årsstämma
2018-02-05 - Bokslutskommuniké 2017
2017-10-24 - Kvartalsrapport 2017-Q3
2017-07-25 - Kvartalsrapport 2017-Q2
2017-04-27 - Kvartalsrapport 2017-Q1
2017-03-10 - X-dag ordinarie utdelning EMBLA 1.95 DKK
2016-03-11 - X-dag ordinarie utdelning EMBLA 0.12 DKK
2016-03-10 - Årsstämma
2016-02-02 - Bokslutskommuniké 2015
2015-10-22 - Kvartalsrapport 2015-Q3
2015-07-23 - Kvartalsrapport 2015-Q2
2015-04-29 - Kvartalsrapport 2015-Q1
2015-03-12 - Årsstämma
2015-02-05 - Bokslutskommuniké 2014
2014-10-24 - Analytiker möte 2014
2014-10-23 - Kvartalsrapport 2014-Q3
2014-07-25 - Analytiker möte 2014
2014-07-24 - Kvartalsrapport 2014-Q2
2014-04-30 - Analytiker möte 2014
2014-04-29 - Kvartalsrapport 2014-Q1
2014-03-14 - Årsstämma
2014-02-05 - Bokslutskommuniké 2013
2013-10-24 - Analytiker möte 2013
2013-10-23 - Kvartalsrapport 2013-Q3
2013-07-24 - Kvartalsrapport 2013-Q2
2013-04-24 - Kvartalsrapport 2013-Q1
2013-03-15 - Årsstämma
2013-02-06 - Bokslutskommuniké 2012
2012-11-28 - Kapitalmarknadsdag 2012
2012-11-27 - Kapitalmarknadsdag 2012
2012-10-24 - Analytiker möte 2012
2012-10-23 - Kvartalsrapport 2012-Q3
2012-07-25 - Kvartalsrapport 2012-Q2
2012-04-24 - Kvartalsrapport 2012-Q1
2012-03-16 - Årsstämma
2012-02-08 - Bokslutskommuniké 2011
2011-10-27 - Kvartalsrapport 2011-Q3
2011-07-28 - Kvartalsrapport 2011-Q2
2011-03-04 - Årsstämma

Beskrivning

LandIsland
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Embla Medical är ett isländskt bolag verksamma inom hälsa och sjukvård. Idag innehas affärsinriktning mot utvecklandet av benproteser, artros samt relaterad skadehantering. Produkterna är anpassade för olika åldrar och förutsättningar beroende på patientens svårighetsgrad. Verksamheten är etablerad globalt med störst marknad inom Europa följt av Nordamerika. Embla Medical grundades under 1971 och har sitt huvudkontor i Reykjavik.
2021-03-25 11:30:53

Global Prosthetics and Orthopaedics Innovation Leader Recognized by UN Agency for Leadership in Patents for Conventional and Emerging Mobility Assistive Technologies

REYKJAVIK, Iceland, March 25, 2021 - Össur (Nasdaq: OSSR), a global leader in the orthotics and prosthetics (O&P) industry with a rich history of ground-breaking innovations, has been recognized by the World Intellectual Property Organization (WIPO) for its intellectual property leadership in conventional mobility assistive technology. WIPO is a specialized agency of the United Nations and serves as the global forum for intellectual property policy, services, information and cooperation worldwide.

The WIPO Technology Trends Report 2021: Assistive Technologies is the first study to systematically investigate patenting and technology trends across assistive technology at scale, analyzing data on patent filings from 1998-2019.

Key findings in the report show that Össur ranks second in the world for top patent applicants in conventional mobility assistive technologies, following only Toyota and ranking among such other global leaders as Panasonic, Honda and Stryker.

Össur is also listed among the top applicants in patent filings for advanced prosthetics and exoskeletons, and ranks 12th in the world among top patent applicants for emerging mobility assistive technologies. The report notes that patents for advanced prosthetics, including neuroprosthetics - also known as "mind-controlled" prostheses, a field that Össur pioneered with the world's first-in-man cases in 2015 - as well as smart and 3D printed prosthetics and exoskeletons, have grown at a 24% average annual growth rate.

Össur's accomplishments are especially notable considering that WIPO reported that patents for assistive technologies to enable mobility have been the leading area of filings since 2014, and that the number of average annual patent filings in this area overshadow the total combined number of filings in the six other domains covered by the report, comprised of cognition, communication, hearing, environment, self-care, and vision.

According to WIPO's report, over 1 billion people currently need assistive technology - a figure expected to double in the next decade as populations age. Continuing innovation is cited as a primary factor in greatly improving the lives of persons with functional limitations, helping them overcome daily obstacles in navigating their environments, communicating, working and living independently.

The report also highlights imagery of Össur's Bionic RHEO KNEE®, and a case study on Össur's Pro-Flex® range of prosthetic feet, which is covered by over 20 patents and features a variety of technological advances intended to improve a user's stability and energy efficiency, and produce a highly natural gait and increased range of ankle motion when compared to other conventional carbon fiber prostheses.

"We are honored by WIPO's acknowledgment of our company's contributions to new innovations that can help more people achieve greater mobility. Since Össur was founded in 1971 and first recognized for our innovative silicone liner, we have continued building upon this legacy of innovation, fueled by our commitment to apply advanced technological approaches that can help even more people enjoy life without limitations," said Jon Sigurdsson, Össur President and CEO. "Receiving this acknowledgment during our 50[th] anniversary gives us one more thing to celebrate, and also inspires us to continue raising the bar even further as we continue progressing as a company."